SCHEMBL5768709

SCHEMBL5768709

CCOc1cccc2cc(C(=O)NC[C@@H]3NCCc4c3sc(NC(=O)C(=O)O)c4C(=O)O)oc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.57
HRH3 Q9Y5N1 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
ALDH1A1 P00352 2/20 0.38
GLA P06280 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA4 P43681 1/20 0.37
RAB9A P51151 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPRB P23467 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5770241 0.84 PTPN1 (0.56) PTPN1ALDH1A1RAB9APTPN2PTPRB
SCHEMBL5771216 0.80 PTPN1 (0.57) PTPN1ALDH1A1HDAC1HDAC2KDM4E
SCHEMBL5770525 0.78 PTPN1 (0.65) PTPN1MEN1KMT2AALDH1A1RAB9A
SCHEMBL5770158 0.78 PTPN1 (0.63) PTPN1PTPN2
SCHEMBL5770624 0.78 PTPN1 (0.61) PTPN1ALDH1A1PTPN2MAPT
SCHEMBL5769588 0.76 PTPN1 (0.59) PTPN1MEN1KMT2ARAB9A
SCHEMBL5767679 0.76 PTPN1 (0.81) PTPN1ALDH1A1RAB9APTPN2KDM4E
SCHEMBL5769149 0.76 PTPN1 (0.81) PTPN1ALDH1A1RAB9APTPN2KDM4E
SCHEMBL5769484 0.76 PTPN1 (0.59) PTPN1ALDH1A1PTPN2PTPRBMAPT
SCHEMBL5769077 0.75 PTPN1 (0.59) PTPN1MEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301516-B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK AS (DK) 2006-03-22 EP disclosed
US-6613903-B2 Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-1301516-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2003-04-16 EP disclosed
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) NOVO NORDISK A/S (DK) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) PTPRO, PTPN1, PTPRS PTPN1 2/4885HRH3 3815/4885MEN1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.